

## National CPE antibiogram – 2016/17 isolates

	ALL CPE (n= 93)	OXA-48-like (n=23)	MBLs (n=68)
	S%		
Amikacin	52.7	69.6	47.1
Amoxicillin-Clavulanate (f)	0	0	0
Ampicillin	0	0	0
Aztreonam	15.1	17.4	14.7
Cefepime	5.4	21.7	0
Ceftazidime	6.5	26.1	0
Ceftolozane-Tazobactam	8.6	34.8	0
Ceftriaxone	4.3	17.4	0
Cefuroxime	2.2	8.7	0
Cephalexin	3.2	13	0
Ciprofloxacin	15.1	13	16.2
Colistin*	98.9	95.7	100
Ertapenem	1.1	4.3	0
Fosfomycin w/G6P	94.6	100	94.1
Gentamicin	39.8	47.8	36.8
Imipenem	17.2	65.2	1.47
Mecillinam#	53.3	81.3	43.2
Meropenem\$	19.4	69.6	2.94
Nitrofurantoin#	96.7	100	95.5
Norfloxacin	11.8	13	16.2
Piperacillin-Tazobactam	2.2	0	2.9
Tigecycline	79.6	78.3	82.4
Tobramycin	32.3	47.8	27.9
Trimethoprim	20.4	26.1	19.1
Trimethoprim-Sulfamethoxazole	23.7	30.4	22.1

\* excludes *Prov. stuartii* and *M.morganii*

# E.coli only

\$ All isolates >0.125 mg/L

≥ 90% Susceptible

70 - 89% Susceptible

< 70% Susceptible

**New Zealand surveillance isolates provided by ESR, funded by the Ministry of Health with the cooperation of the diagnostic laboratories**